Agilent Technologies has release its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent high-resolution LC/MS for oligonucleotide purity analysis and sequence confirmation.
Oligonucleotides are a class of molecules attracting increased interest as therapeutics in the biopharma industry. Oligonucleotides target gene expression through several mechanisms and offer considerable promise for addressing a wide range of diseases. However, challenges remain in developing oligonucleotide-based biotherapeutics, including finding ways to enhance their in vivo stability, more confidently and precisely target their delivery, and quickly confirm sequences.
Agilent MassHunter BioConfirm 12.0 software introduces enhancements to existing capabilities for protein analysis and adds support for oligonucleotide analysis. The addition of oligonucleotide support significantly extends the capabilities of MassHunter BioConfirm, adding critical functionality for assessing oligonucleotide purity and sequence confirmation – important analytical steps in the use of oligonucleotides for biotherapeutics and vaccine research and development.
The new MassHunter BioConfirm 12.0 workflows allow researchers to identify full-length products and potential impurities. The innovative MS/MS-based sequence confirmation enables confirmation of oligonucleotide sequences in minutes instead of days or weeks of manual interpretation. MassHunter BioConfirm 12.0 also has the built-in flexibility for software customization to accommodate specific oligo nomenclatures and continues to provide support to ensure regulatory compliance and preservation of data integrity.
For more information, visit: https://bit.ly/3Owlzo5